The Thoratec ventricular assist device (VAD) offers a final hope for survival in patients with severe cardiogenic shock unresponsive to conventional therapy. In select patients, these pneumatically activated prosthetic ventricles maintain organ perfusion pending recovery of the native heart or cardiac transplant. A detailed review of Thoratec VAD operation, its impact on the circulatory pathway and hemodynamic monitoring, and troubleshooting guidelines specific to these patients are presented. A nursing diagnosis framework assists with the identification and management of problems such as impaired cardiac output and gas exchange, as well as altered mobility, nutrition, and coping. Current information regarding the etiology and management of complications such as bleeding, infection, and end-organ failure are reviewed. A case study presentation offers guidelines for weaning patients from the VAD and includes a comprehensive nursing care plan for these challenging patients.
Download full-text PDF |
Source |
|---|---|
| http://dx.doi.org/10.4037/15597768-1991-3017 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Treating Older Patients in Cardiogenic Shock With a Microaxial Flow Pump: Is It DANGERous?
J Am Coll Cardiol
November 2024
Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark; Department of Cardiology, Odense University Hospital, Odense, Denmark; Department of Clinical Research, University of Southern, Odense, Denmark. Electronic address:
Article Synopsis
- This study examines how age influences the effectiveness of microaxial flow pump (mAFP) treatment for patients suffering from ST-elevation myocardial infarction (STEMI) and cardiogenic shock (CS), using data from the DanGer Shock trial involving 355 participants.
- Findings reveal that mortality rates significantly increase with age, from 31% in the youngest group to 73% in the oldest, showing younger patients (<77 years) benefit more from mAFP treatment (lower mortality), while older patients (≥77 years) do not have the same advantage.
- The study also notes that complications were more common in the mAFP group, but overall, age significantly impacted survival outcomes, highlighting
Microaxial Flow Pump Use and Renal Outcomes in Infarct-Related Cardiogenic Shock: A Secondary Analysis of the DanGer Shock Trial.
Circulation
December 2024
Department of Cardiology, Copenhagen University Hospital-Rigshospitalet, Copenhagen, Denmark (C.H., R.P.B., T.E., L.H., J.E.M.).
Background: In DanGer Shock (the Danish-German Cardiogenic Shock trial), use of a microaxial flow pump (mAFP) in patients with ST-segment-elevation myocardial infarction-related cardiogenic shock led to lower all-cause mortality but higher rates of renal replacement therapy (RRT). In this prespecified analysis, rates and predictors of acute kidney injury (AKI) and RRT were assessed.
Methods: In this international, randomized, open-label, multicenter trial, 355 adult patients with ST-segment-elevation myocardial infarction-related cardiogenic shock were randomized to mAFP (n=179) or standard care alone (n=176).
Left Ventricular Assist Device Pump Obstruction Reduces Native Heart Efficiency.
Bioengineering (Basel)
December 2023
Bioengineering Program, San Diego State University, San Diego, CA 92182, USA.
Obstruction of the LVAD flow path can occur when blood clots or tissue overgrowth form within the inflow cannula, pump body, or outflow graft, and it can lead to thrombus, embolism, and stroke. The goal of this study was to measure the impact of progressive pump inflow obstruction on the pressure and flow dynamics of the LVAD-supported heart using a mock circulatory loop. Pump obstruction (PO) was produced by progressively blocking a fraction of the LVAD inlet area.
View Article and Find Full Text PDFThe aim of this investigation was to characterize the hemostatic status of heart failure patients with implanted left ventricular assist devices (LVADs) to propose a mechanism associated with bleeding. Patients (n = 300) from 23 US hospitals were enrolled in the PREVENtion of HeartMate II Pump Thrombosis through Clinical Management (PREVENT) study. A biobank was established with serum and plasma samples prospectively collected from a cohort of 175 patients preimplant baseline (BL) and 3 months (3M) postimplant.
View Article and Find Full Text PDFPostoperative tolvaptan use in left ventricular assist device patients: The TOLVAD randomized pilot study.
Artif Organs
December 2022
Columbia University Irving Medical Center, Weill Cornell Medicine, New York, New York, USA.
Purpose: Tolvaptan, a selective vasopressin type-2 antagonist, has been shown to increase serum sodium (Na) and urine output in hyponatremic left ventricular assist device (LVAD) patients in retrospective studies. In this prospective randomized pilot study, we aimed to assess the efficacy of tolvaptan in this population.
Methods: We conducted a prospective, randomized, non-blinded pilot study of LVAD recipients with post-operative hyponatremia (Na < 135 mEq/L) (NCT05408104).
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!